Showing results (561-570 of 1,376) with videos related to

Sort By:
Pageof 138
Neuro-Oncology Advances|May 30, 2024
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive gliomaAlberto Picca, Anna Luisa Di Stefano, Julien Savatovsky, et al.
Neuro-Oncology Advances|June 10, 2024
Leveraging murine models of the neurofibromatosis type 1 cancer predisposition syndrome to elucidate the cellular circuits that drive pediatric low-grade glioma formation and progressionDavid H Gutmann
Neuro-Oncology Advances|April 15, 2024
Potential roles for efferocytosis in glioblastoma immune evasionIan A J Lorimer
Neuro-Oncology Advances|April 10, 2024
Plasma ctDNA enables early detection of temozolomide resistance mutations in gliomaJordan J Jones, Kate L Jones, Stephen Q Wong, et al.
Neuro-Oncology Advances|April 10, 2024
Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial designUgur Sener, Mahnoor Islam, Mason Webb, et al.
Neuro-Oncology Advances|April 10, 2024
The outcomes measured and reported in intracranial meningioma clinical trials: A systematic reviewChristopher P Millward, Sumirat M Keshwara, Terri S Armstrong, et al.
Neuro-Oncology Advances|April 9, 2024
GD3 ganglioside is a promising therapeutic target for glioma patientsVictoria Hein, Nathalie Baeza-Kallee, Alexandre Bertucci, et al.
Neuro-Oncology Advances|January 22, 2026
Improved target volume delineation for stereotactic radiosurgery in brain metastases using post-contrast 3D T1 TSE black-blood MRIZhao Hui Chen Zhou, Rafael D Ambrosi, Amaya Hilario, et al.
Neuro-Oncology Advances|January 30, 2026
Age-dependent glioma progression and functional decline in a syngeneic murine model: Host vulnerabilities and opportunities for targeted interventionHeloise Leblanc, Michelle Buzharsky, Xaralabos Varelas, et al.
Neuro-Oncology Advances|January 16, 2026
Preclinical assessment of checkpoint blockade combined with DNA methyltransferase inhibition in high-risk pediatric brain tumors reveals limited therapeutic synergyDeepak Kumar Mishra, Shelli M Morris, Dean Popovski, et al.
Pageof 138